August 14, 2023 01:56 PM EDT
Deals
Pharma

Ra­dius Phar­ma sells off part of its roy­al­ties, mile­stones in breast can­cer drug Orser­du

Katherine Lewin

News Reporter

Ra­dius Phar­ma­ceu­ti­cals is pulling in an up­front pay­ment of $130 mil­lion from DRI Health­care as part of a roy­al­ty pur­chase agree­ment for its breast can­cer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times